Table 1.
Baseline characteristics of the 218 patients§.
| No fractures (n = 170) | Fractures (n = 48) | PValue | |
|---|---|---|---|
| General characteristics | |||
| Age (years) | 57 (37–70) | 69 (51–75) | 0.0072† |
| CKD evolution (years) | 12 (7–18) | 11 (7.5–16) | 0.56† |
| CKD to first DXA (years) | 4 (1–9) | 5 (2–8.5) | 0.29† |
| BMI (Kg/m2) | 26.4 (±6.37) | 26.1 (±4.57) | 0.27 |
| Lumbar spine BMD (g/cm2) | 0.872 (±0.151) | 0.767 (±0.151) | <0.000⁎ |
| Lumbar spine T-score | −1.57 (±1.37) | −2.51 (±1.39) | <0.000⁎ |
| Total hip BMD (g/cm2) | 0.784 (±0.151) | 0.674 (±0.160) | <0.000⁎ |
| Total hip T-score | −1.27 (±1.11) | −2.13 (±1.18) | <0.000⁎ |
| aLumbar spine diagnosis | |||
| Normal | 53 (31.1) | 5 (10.4) | |
| Osteopenia | 75 (44.1) | 18 (37.5) | |
| Osteoporosis | 42 (24.7) | 25 (52.1) | <0.000⁎ |
| aTotal hip diagnosis | |||
| Normal | 72 (42.3) | 10 (20.8) | |
| Osteopenia | 76 (44.7) | 16 (33.3) | |
| Osteoporosis | 22 (12.9) | 22 (45.8) | <0.000⁎ |
| Fracture events | NS‡ | ||
| Lumbar spine | – | 20 (36.3) | |
| Femur | – | 18 (32.7) | |
| Radius | – | 4 (7.27) | |
| FFb | – | 13 (23.6) | |
| CKD stage | |||
| 3a | 51 (30) | 7 (14.5) | |
| 3b | 42 (24.7) | 11 (22.9) | |
| 4 | 37 (21.7) | 15 (31.2) | |
| 5 | 40 (23.5) | 15 (31.2) | 0.12 |
| Laboratory values | |||
| GFR mL/min/m2 | 30.6 (±17.6) | 25.92 (±16.4) | 0.09 |
| PTH pg/mL, n = 126 | 140.2 (62.7–341.4) | 139.2 (71.9–322.7) | 0.52† |
| Serum calcium mg/dL, n = 189 | 9.32 (±0.79) | 9.33 (±0.75) | 0.99 |
| Corrected calcium mg/dL, n = 177 | 9.48 (±0.67) | 9.45 (±0.67) | 0.83 |
| Serum phosphate mg/dL, n = 184 | 4.04 (±1.11) | 4.05 (±1.15) | 0.95 |
| 25 (OH) D3 ng/mL, n = 95 | 20.4 (±10.3) | 17.2 (±9.02) | 0.17 |
| Albumin g/dL, n = 191 | 3.86 (±0.65) | 3.85 (±0.56) | 0.96 |
| Comorbidities | |||
| Type 2 Diabetes | 70 (41.1) | 26 (54.1) | 0.10 |
| Systemic lupus erythematosus | 28 (16.4) | 7 (14.5) | 0.75 |
| Hypothyroidism | 46 (27) | 17 (35.4) | 0.25 |
| Renal transplant | 51 (30) | 8 (16.6) | 0.06 |
| Calcium treatment | 70 (41.1) | 26 (54.1) | 0.14 |
| Vitamin D treatment | 72 (42.3) | 25 (52) | 0.11 |
| Osteoporosis treatment | 12 (7) | 8 (16.6) | 0.61 |
| Immunosuppressive treatment | 64 (37.6) | 10 (20.8) | 0.03⁎ |
§
Data are given as the mean ± SD or percentage.
†
Data are given as median and range.
‡
Any statistical difference between fracture site.
a
T-score diagnosis based on the WHO standards.
b
Fragility fractures as defined by WHO guidelines.
⁎
Statistical significance (p < 0.05).